Literature DB >> 20523967

Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations.

J A Johnson1, Y Yasui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20523967     DOI： 10.1007/s00125-010-1780-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  23 in total

1.  Observational studies of treatment effectiveness: some cautions.

Authors:  Andreas Laupacis; Muhammad Mamdani
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

2.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Authors:  Panagiotis N Papanikolaou; Georgia D Christidi; John P A Ioannidis
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

3.  Does insulin therapy promote, reduce, or have a neutral effect on cancers?

Authors:  Hertzel C Gerstein
Journal:  JAMA       Date:  2010-02-03       Impact factor: 56.272

4.  Insulin glargine and cancer--an unsubstantiated allegation.

Authors:  Satish K Garg; Irl B Hirsch; Jay S Skyler
Journal:  Diabetes Technol Ther       Date:  2009-08       Impact factor: 6.118

5.  Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Authors:  Samantha L Bowker; Sumit R Majumdar; Paul Veugelers; Jeffrey A Johnson
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

6.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

7.  Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.

Authors:  P D Home; S E Kahn; N P Jones; D Noronha; H Beck-Nielsen; G Viberti
Journal:  Diabetologia       Date:  2010-06-08       Impact factor: 10.122

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

10.  Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research.

Authors:  Bruce B Duncan; Maria I Schmidt
Journal:  Diabetes Care       Date:  2009-09       Impact factor: 19.112
View more
  4 in total

Review 1.  Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence.

Authors:  J A Johnson; B Carstensen; D Witte; S L Bowker; L Lipscombe; A G Renehan
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

2.  Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus.

Authors:  Yu-Xiao Yang; Laurel A Habel; Angela M Capra; Ninah S Achacoso; Charles P Quesenberry; Assiamira Ferrara; Theodore R Levin; James D Lewis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-11       Impact factor: 4.254

3.  The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea.

Authors:  Da Young Lee; Ji Hee Yu; Sanghyun Park; Kyungdo Han; Nam Hoon Kim; Hye Jin Yoo; Kyung Mook Choi; Sei Hyun Baik; Nan Hee Kim; Ji A Seo
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

4.  Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort.

Authors:  Rachel Dankner; Ran Balicer; Paolo Boffetta; Lital Keinan Boker; Sylvan Wallenstein; Laurence Freedman; Margalit Goldfracht; Jesse Roth; Ronald Tamler; Derek LeRoith
Journal:  BMC Cancer       Date:  2012-08-23       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.